These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18568435)

  • 1. A model to decompose the performance of supplementary private health insurance markets.
    Leidl R
    Int J Health Care Finance Econ; 2008 Sep; 8(3):193-208. PubMed ID: 18568435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk selection and heterogeneous preferences in health insurance markets with a public option.
    Polyakova M
    J Health Econ; 2016 Sep; 49():153-68. PubMed ID: 27454199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs, commitment and locality: a comparison of for-profit and not-for-profit health plans.
    Inquiry; 2004; 41(2):116-29. PubMed ID: 15449428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical service provider networks.
    Mougeot M; Naegelen F
    Health Econ; 2018 Aug; 27(8):1201-1217. PubMed ID: 29774623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can the regulator show evidence of (no) risk selection in health insurance markets? Conceptual framework and empirical evidence.
    van de Ven WP; van Vliet RC; van Kleef RC
    Eur J Health Econ; 2017 Mar; 18(2):167-180. PubMed ID: 26837411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the medical loss ratio a good target measure for regulation in the individual market for health insurance?
    Karaca-Mandic P; Abraham JM; Simon K
    Health Econ; 2015 Jan; 24(1):55-74. PubMed ID: 24123608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pricing behaviour of nonprofit insurers in a weakly competitive social health insurance market.
    Douven RC; Schut FT
    J Health Econ; 2011 Mar; 30(2):439-49. PubMed ID: 21295365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymmetric Information in Iranian's Health Insurance Market: Testing of Adverse Selection and Moral Hazard.
    Lotfi F; Abolghasem Gorji H; Mahdavi G; Hadian M
    Glob J Health Sci; 2015 Apr; 7(6):146-55. PubMed ID: 26153155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal cost reimbursement of health insurers to reduce risk selection.
    Kifmann M; Lorenz N
    Health Econ; 2011 May; 20(5):532-52. PubMed ID: 20572200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual insurance: health insurers try to tap potential market growth.
    November EA; Cohen GR; Ginsburg PB; Quinn BC
    Res Brief; 2009 Nov; (14):1-8. PubMed ID: 19899193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical Underwriting In Long-Term Care Insurance: Market Conditions Limit Options For Higher-Risk Consumers.
    Cornell PY; Grabowski DC; Cohen M; Shi X; Stevenson DG
    Health Aff (Millwood); 2016 Aug; 35(8):1494-503. PubMed ID: 27503976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scope and Incentives for Risk Selection in Health Insurance Markets With Regulated Competition: A Conceptual Framework and International Comparison.
    van Kleef RC; Reuser M; McGuire TG; Armstrong J; Beck K; Brammli-Greenberg S; Ellis RP; Paolucci F; Schokkaert E; Wasem J
    Med Care Res Rev; 2024 Jun; 81(3):175-194. PubMed ID: 38284550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of independent agents in the success of health insurance market reforms.
    Hall MA
    Milbank Q; 2000; 78(1):23-45, i-ii. PubMed ID: 10834080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of government in health insurance markets with adverse selection.
    Feldman R; Escribano C; Pellisé L
    Health Econ; 1998 Dec; 7(8):659-70. PubMed ID: 9890328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching benefits and costs in competitive health insurance markets: A conceptual framework and empirical evidence from the Netherlands.
    Duijmelinck DM; Mosca I; van de Ven WP
    Health Policy; 2015 May; 119(5):664-71. PubMed ID: 25530069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Supplementary insurance as a switching cost for basic health insurance: Empirical results from the Netherlands.
    Willemse-Duijmelinck DMID; van de Ven WPMM; Mosca I
    Health Policy; 2017 Oct; 121(10):1085-1092. PubMed ID: 28855064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comment on Neudeck and Podczeck's "adverse selection and regulation in health insurance markets".
    Encinosa W
    J Health Econ; 2001 Jul; 20(4):667-73. PubMed ID: 11463193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Provider-owned insurers in the individual market.
    Howard DH; Herring B; Graves J; Trish E
    Am J Manag Care; 2018 Dec; 24(12):e393-e398. PubMed ID: 30586488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No significant association between anesthesia group concentration and private insurer payments in the United States.
    Sun EC; Dexter F; Macario A; Miller TR; Baker LC
    Anesthesiology; 2015 Sep; 123(3):507-14. PubMed ID: 26192028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key drivers of financial performance of insurers in the Affordable Care Act market exchange.
    McCue M; Hall MA; Palazzolo J
    Health Serv Manage Res; 2020 Aug; 33(3):130-135. PubMed ID: 31729257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.